If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
54
results.
Updated on
29/08/2025 [06:45:00]
Absstract of: US2025270254A1
The present disclosure provides a probe specifically binding to CD138, a kit and a microfluidic chip comprising the probe, and a method of diagnosing diffuse large B-cell lymphoma in a subject using the probe, the kit, or the microfluidic chip. The present disclosure also provides a method of screening the probe for diagnosing diffuse large B-cell lymphoma.
Absstract of: AU2025213596A1
Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid 5 residue positions 33 to 109 of human integrin β7. Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid 5 residue positions 33 to 109 of human integrin ß7. ug r o v i d e d i s a n a c t i v e i n g r e d i e n t o f a p h a r m a c e u t i c a l u g c o m p o s i t i o n f o r t r e a t i n g m y e l o m a p e c i f i c a l l y , p r o v i d e d i s a n a n t i b o d y w h o s e e p i t o p e i s p r e s e n t i n t h e r e g i o n o f t h e a m i n o a c i d r e s i d u e p o s i t i o n s t o o f h u m a n i n t e g r i n ß
Absstract of: US2025270193A1
The present disclosure provides compounds which are useful in the treatment of oncological disorders, more particularly arylimidamides useful in the treatment of leukemias. Exemplary compounds include an azole moiety connected to a phenoxy or pyridyloxy moiety via an alkylene chain, the phenoxy or pyridyloxy moiety attached to a benzimidamide or pyridylimidamide function.
Absstract of: AU2025217281A1
Provided herein, in some embodiments, are methods for reducing the risk of developing progressive multifocal leukemia in patients undergoing natalizumab therapy by switching to an extended interval dosing (EID) schedule. Provided herein, in some embodiments, are methods for reducing the risk of developing progressive multifocal leukemia in patients undergoing natalizumab therapy by switching to an extended interval dosing (EID) schedule. ug r o v i d e d h e r e i n , i n s o m e e m b o d i m e n t s , a r e m e t h o d s f o r r e d u c i n g t h e r i s k o f d e v e l o p i n g p r o g r e s s i v e m u l t i f o c a l l e u k e m i a i n p a t i e n t s u n d e r g o i n g n a t a l i z u m a b t h e r a p y b y u g s w i t c h i n g t o a n e x t e n d e d i n t e r v a l d o s i n g ( ) s c h e d u l e
Absstract of: WO2025174079A1
The present invention relates to a composition comprising an anti-CD20 antibody and a PIKfyve inhibitor for preventing or treating CD20 positive cancer such as B cell lymphoma. The present invention can maximize the anticancer effect of an anti-CD20 antibody, specifically, obinutuzumab, by co-administering an anti-CD20 antibody and a PIKfyve inhibitor, which is a negative regulator of a tumor cell killing mechanism thereof. In addition, by using PIKfyve as a screening target, the present invention can rapidly identify, with high reliability, combination therapy candidate agents that can synergistically enhance the direct cell death (DCD), lysosomal membrane permeabilization (LMP), and subsequent cancer cell-killing activity of anti-CD20 antibodies.
Absstract of: US2025262299A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and lenalidomide.
Absstract of: WO2025174664A1
Minor histocompatibility antigens (mHAgs) associated with graft versus leukemia (GvL) clinical outcomes identified by single nucleotide polymorphisms (SNPS) and uses thereof are described.
Absstract of: US2025263412A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a heteroaryl substituted oxadiazole structure which function as non-hydroxamate histone deacetylase 6 (HDAC6) inhibitors, and their use as therapeutics for the treatment of metabolic disorders (e.g., obesity, Diabetes), neurological disorders (e.g., Alzheimer's disease, Parkinson disease, Huntington disease), cancer (e.g., multiple myeloma, biliary tract cancer, non-small cell lung cancer, chronic lymphocytic leukemia) and other conditions related to HDAC6 activity (e.g., Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT)).
Absstract of: US2025263440A1
A peptide, compound, or conjugate that can bind CD38. The CD38-binding peptide, compound, or conjugate has a sequence selected from the group consisting of SEQ ID NOs. 1-34. The CD38-binding peptides, compounds, or conjugates are useful for treating CD38-associated conditions, disorders, or diseases, such as cancer, leukemia, or myelomas.
Absstract of: US2025263740A1
An object of the present invention is to provide a novel non-replicating bovine leukemia virus (BLV) and a producing cell thereof. According to the present invention, there is provided a bovine leukemia virus (BLV) in which at least a part of the function of a pol gene is deficient. Also, according to the present invention, there is provided a non-replicating BLV-producing cell comprising a gene of a BLV in which at least a part of the function of a pol gene is deficient. The present invention is advantageous in that it can provide a BLV vaccine which is highly immunogenic, and is highly safe without replicating in an infected subject.
Absstract of: WO2024077376A1
Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of myelodysplastic syndrome (MDS) or leukemia such as AML is also described.
Absstract of: WO2025169136A1
The present disclosure provides, among other things, a method for treating cancer by administering two or more doses of cord blood derived natural killer cells expressing CD19 targeted chimeric antigen receptor to a subject in need thereof. The present disclosure provides a dosing regimen, for example, 800 million CD19 CAR NK cells administered in three doses for treating a cancer, for example, relapsed or refractory large B cell lymphoma.
Absstract of: WO2025170902A1
Provided herein are methods of treating a subject who has multiple myeloma and has received an initial therapy, including a stem cell transplantation. Infusions of chimeric antigen receptor (CAR)-T cells comprising a BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 x 105 to 5.0 x 106 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.
Absstract of: AU2024215598A1
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Absstract of: WO2025170888A1
Provided herein are combination therapies for treating blood cancer, in particular, acute myeloid leukemia, by concurrently targeting AXL and PD-1.
Absstract of: US2025257027A1
The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compounds are also provided.
Absstract of: US2025257058A1
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Absstract of: US2025255889A1
As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial using the agent to treat CLL.
Absstract of: WO2025168847A1
The present disclosure relates to a combination of a chimeric antigen receptor (CAR) and a modified CD200 receptor (CD200R). More in particular, a combination of a CAR targeting an antigen highly expressed in cancers which also typically express CD200, such as Hodgkin lymphoma, with a modified CD200R has been found useful in the treatment of such cancers. The present disclosure further relates to polynucleic acids, vectors, immune cells, pharmaceutical compositions encoding or comprising said combination, the same for use in the treatment of cancer and methods of preparation of said immune cells.
Absstract of: WO2025171395A1
Disclosed herein are compounds, compositions and methods directed to strategies that selectively kill cells comprising mutant splicing factors but conserve wild-type cells, and treating diseases and disorders in a subject (e.g., cancer, myelodysplastic syndromes, acute myeloid leukemia, and the like).
Absstract of: WO2025170547A1
The present invention relates to a CD19-specific chimeric antigen receptor comprising a CD28/CD40 co-stimulatory domain (CAR-CD19z.CD28.CD40) that has been genetically modified, particularly in the signaling domains of the CD28/CD40 co- stimulatory domain, and transduced into T cells to generate specifically modified T cells expressing CAR-CD19z.CD28.CD40 on their surface. The said T cells are used for the treatment of cancers expressing CD19 antigen on the cell surface, such as leukemia and lymphoma. Additionally, they can effectively reduce the relapse or resistance to treatment.
Absstract of: WO2025167758A1
Provided in the present invention are a class of FTO inhibitors, a preparation method therefor and the use thereof. Specifically, disclosed in the present invention are a 2-(substituted phenyl hetero) aromatic formate as shown in general formula (I) and a derivative compound thereof, and a pharmaceutically acceptable salt, hydrate or solvate thereof. The compound can be used as an FTO target inhibitor for treating diseases associated with the FTO target, such as leukemia, lymphoma, myelodysplastic syndrome, obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's disease, breast cancer, kidney cancer, colorectal cancer, pancreatic cancer, liver cancer, small cell lung cancer, human bone marrow rhabdomyosarcoma, pancreatic cancer and malignant glioblastoma.
Absstract of: EP4600260A1
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-4, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a host cell having the nucleic acid molecule integrated into the genome, as well as a method for preparing keratin YK93-4 and a pharmaceutical composition of keratin YK93-4. Further provided is the use of the above-described keratin YK93-4 and related products thereof in the preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, uterus myoma, hyperplasia of prostate, etc.
Absstract of: EP4600259A1
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a host cell having the nucleic acid molecule integrated into the genome, as well as a method for preparing keratin YK93-8 and a pharmaceutical composition of keratin YK93-8. Further provided is the use of the above-mentioned keratin YK93-8 and other products in the preparation of drugs, such as a drug for treating hyperplasia of prostate, lymphoma, melanoma, breast cancer, lung cancer and uterine myoma, an analgesic, a lactation drug and a coagulant.
Nº publicación: EP4600258A1 13/08/2025
Applicant:
INST MATERIA MEDICA CAMS [CN]
INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Absstract of: EP4600258A1
The present invention pertains to the field of biopharmaceuticals and provides a keratin YK93-6, a nucleic acid molecule encoding same, an expression vector comprising the nucleic acid molecule, a host cell that contains the expression vector or whose genome is integrated with the nucleic acid molecule, a preparation method therefor, and a pharmaceutical composition thereof. The present invention also provides use of the described keratin YK93-6 among other products in the preparation of medicaments for treating prostatic hyperplasia, lymphoma, melanoma, pain, lactation disorders, breast cancer, lung cancer, hysteromyoma, coagulation disorders, and the like .
BOPI
Electronic site
